All In Biotech

Drug Trial Radar · NCT07023731

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

May 29, 2025

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Arvinas Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806. Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be the first time ARV-806 will be used in people. The investigational drug will be given through a vein. This is called intravenous (IV) infusion. This study will include 2 parts: In Part A (Phase 1), different small groups of participants will receive lower to higher doses of ARV-806. Adults with advanced cancers having a specific KRAS mutation will be included. In Part B (Phase 2), participants will be assigned to receive one of up to 2 dose levels decided by the information from Part A. Part B will include participants with advanced pancreatic ductal cancer having a specific KRAS mutation.

Conditions

  • KRAS G12D Mutation
  • Advanced Solid Cancer

Interventions

  • ARV-806Drug

    Intravenous infusion at assigned dose and dosing schedule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806Time frame: 28 days from first ARV-806 administration
  2. Part A (Phase 1): Number of participants with AEsTime frame: From the study baseline to at least 28 days after last dose of ARV-806
  3. Part B (Phase 2): Overall Response Rate (ORR)Time frame: Approximately 2 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    New Haven, Connecticut

  • Clinical Trial Site

    Tampa, Florida

  • Clinical Trial Site

    Indianapolis, Indiana

  • Clinical Trial Site

    Grand Rapids, Michigan

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Huntersville, North Carolina

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    San Antonio, Texas

  • Clinical Trial Site

    Salt Lake City, Utah

  • Clinical Trial Site

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.